Primrose Bio’s Post

Join Advancing RNA, featuring insights from pros like Greg Troiano at Sanofi and April Sena, PhD from Life Edit Therapeutics as we dive into the nitty-gritty of the inbound supply chain for mRNA/LNP therapeutics. Expect in-depth discussions on spotting supply gaps, teaming up for better raw materials, picking the right suppliers, and nailing GMP principles to amp up quality and cut costs. We unpack the challenges and wins in the ever-evolving supply chain for both small- and large-scale RNA therapeutics. #AdvancingRNA #mrna #supplychain https://lnkd.in/e2JxQxqG

#BTI is participating in global efforts within the Wellcome Leap #R3 programme, RNA Readiness + Response, to advance RNA manufacturing and analytical capabilities by helping demonstrate proof of quality in producing mRNA therapeutics through end-to-end, multi-product standardised platforms. The R3 program aims at creating a self-sustaining network of RNA biofoundries to: (1) increase exponentially mRNA-based biologics equitably accessible at reduced cost (2) establish economically sustainable pandemic preparedness Stay tuned for more updates about BTI’s mRNA manufacturing and analytical capabilities. #ASTAR #ASTARBTI #CreatingGrowth #EnhancingLives #mRNA

Join us on February 21, 2024, at 11 AM EST for an insightful discussion on the current state and growth opportunities in the mRNA supply chain. Our Editorial & Community Director, Anna Rose Welch, will be hosting Greg Troiano and April Sena, PhD, industry experts from Sanofi and Life Edit Therapeutics. Together, they'll explore supply chain considerations, identify gaps, and discuss how innovators and suppliers can collaborate to enhance the availability and quality of raw materials for improved mRNA production. Save the date and stay tuned for a deep dive into the world of RNA therapeutics!  https://lnkd.in/gmqnrkaP  #mrna #supplychain #rawmaterials 

Did you miss it? Last month, we introduced our groundbreaking chemical modification search tool! If you are working in oligonucleotide therapeutics, and want to enhance your innovation capabilities, take a look at the link below and explore what this revolutionary tool can do for you! #oligonucleotide #RNA #chemicalmodification #innovation

Did you know that Transfer RNAs (tRNAs) are not just key players in protein translation, but can also give rise to a unique class of small non-coding RNAs with therapeutic potential? This is what we presented yesterday at the mRNA-Based Therapeutic Summit in Berlin! And look here: https://lnkd.in/dikbXkMB Recent research reveals their diverse roles in cancer, challenging the traditional view of tsRNAs as mere byproducts. Stay tuned for a closer look at how tsRNAs revolutionize our understanding of cancer and pave the way for innovative therapies. 🌐🔬 #CancerResearch #RNARevolution #InnovationInMedicine #RNA #TheRibosomeCompany

We are thrilled to share that we have achieved gram-scale synthesis with our ECO Synthesis™ technology platform! This critical technical milestone demonstrates the preparative-scale manufacture of an oligonucleotide, composed of the modified nucleotide building blocks typically used in RNA therapeutics, under process-like conditions. Successful completion of this milestone enables Codexis engineers to initiate a comprehensive assessment of the purity profile for siRNA developed with ECO Synthesis™ technology. Separately, data collected on process-related parameters provides foundational information for early models of the siRNA manufacturing process and allows the Company to open conversations with early access customers on their RNA interference (RNAi) therapeutics manufacturing processes. Early access customer testing is on track to initiate in 2024 ahead of an anticipated full commercial launch in 2026. Read our press release for more details: https://lnkd.in/eePEGqDB #rnai #proteinengineering #enzymeengineering

Join us on October 19th at 8AM PT for a GEN Learning Lab, as our expert panelists discuss the current state of the field, the key challenges hindering widespread adoption of personalized mRNA therapeutics, and what's needed to overcome them. These challenges include the imperative for labs to validate the approach and showcase its efficacy; the necessity for scalability in deployment to reach a broader audience; and the importance of ensuring that the technique is viable for both manufacturers and patients. Our panelists will discuss technologies and strategies for mitigating these challenges and helping the field advance.

Looking back on the discussions at the RNA Leaders' Congress in Basel. It was great to see many researchers gathering to discuss advances and challenges in #RNA therapeutics and vaccines. Thanks to the speakers for sharing their insights. As one of the panelists mentioned, I'm eager to see how we address global health challenges by tackling these 3Es: Entry to cells Escape from endosomes Efficacy #RNA #Oligonucleotides #Synthesizers #Biotech

Eli Lilly’s $409M collaboration with Genetic Leap highlights the growing role of AI in drug discovery, particularly in RNA-targeted therapies. By leveraging AI-driven platforms, this partnership aims to accelerate breakthroughs in treating historically undruggable targets, reflecting a broader trend toward innovation in RNA medicine. With Lilly's recent $700M investment in RNA research, the pharma giant is clearly positioning itself at the forefront of next-gen therapeutics. #EliLilly #GeneticLeap #RNA #PatientCentricOncologyClinicalTrials #AIinHealthcare #DrugDiscovery #RNAResearch #BiotechInnovation #PharmaPartnerships #ArtificialIntelligence #HealthcareInnovation #PrecisionMedicine #Biopharma #RNAtherapeutics #LifeSciences #GeneticResearch #PharmaCollaboration